Know how your drug performs
before they do.
Continuous monitoring of competitor asset performance, adverse events, and real-world market share.
Competitor Drug X shows 15% increase in reported adverse cardiac events in latest EU registry data.
Physician sentiment shifting: 22% of prescribers in Top 10 IDNs actively switching patients to your asset.
Phase 3 trial for Competitor Z delayed by 6 months due to enrollment bottlenecks in oncology cohort.
Real-Time Market Share
Track prescribing patterns and treatment switching dynamics as they happen in the real world, not just through delayed claims data.
Competitor Safety Signals
Monitor the exact adverse event profiles of competing therapies. Identify vulnerabilities in competing clinical profiles early.
Targeted Positioning
Analyze sub-population outcomes to identify precise patient cohorts where your asset demonstrates undeniable superiority.
Stop relying on quarterly reports for real-time decisions.
Frekil allows your commercial and strategy teams to query real-world databases instantly, turning raw data into actionable competitive intelligence.